Seasonal Affective Disorder (SAD) is a type of mood disorder characterized by depression that occurs at the same time period every year. SAD is most common among women aged 15–55. Some major symptoms include fatigue, hopelessness, depression, suicidal thoughts, anxiety, loss of appetite, weight gain, lack of concentration, and social withdrawal. Globally, the prevalence of seasonal affective disorders is increasing at a considerable rate. As per the Helpline Organization, SAD affects nearly 2% of the population, predominantly in women and younger people, which is subsequently increasing the hospital visits across the globe. However, the emergence of new treatment alternatives for SAD is driving the market growth.
Additionally, a number of therapies are available as a treatment option in the high-income countries, which include phytotherapy, psychotherapy, and mind-body techniques. Also, increasing awareness regarding the disorder and its treatment options is augmenting the development of novel drugs, which is positively impacting market growth. People migrating from the elongated summer area to Polar Regions are more likely to suffer from SAD. It is most common in people residing in Egypt, Jacksonville, Cairo, Florida, Austin, Texas, China, or south of South Africa, Durban, Perth, Australia, Cordoba, and Argentina. To attend to the situation, the governments in the region are organizing a number of mental health programs, such as meditation therapies, counseling centers, relaxing programs, yoga centers, and camps to raise awareness regarding SAD and its effect on life. Other factors driving the market include the increasing investments in the healthcare sector, the emergence of new pharmaceutical manufacturers, and prolonged winters.
By type, the Seasonal Affecting Disorders (SAD) Market Is Trifurcated into Fall and Winter Sad, Spring and Summer Sad, and Others.
Fall and winter SAD segment is dominating the SAD market and will continue the same during the forecast period. This can be attributed to a number of factors, including oversleeping, excessive weight gain, tiredness or low energy levels, lack of physical activity, overeating, and lack of exposure to sunlight in winter. For the record, low exposure to sunlight reduces the serotonin and melatonin levels and triggers depression, mood swings, and disrupts the sleeping pattern. The above-mentioned factors are likely to increase the demand for innovative treatment options, such as advanced phytotherapy, and psychotherapy, among others.
By Treatment, the Sad Market Is Segmented Into Self-Care, Phototherapy, Psychotherapy, Medications, Mind-Body Techniques, and Others.
Phototherapy—also known as light therapy—is grabbing one of the highest shares in the SAD market on account of the growing prevalence of SAD and the development of innovative therapy. Phototherapy has fewer side effects, and it is safe and effective when used with antidepressants. Other factors driving the segment include the easy accessibility of products through online platforms and rising awareness among end-users regarding the usage of light therapy products. Similarly, increasing healthcare expenditure in emerging countries such as China and India is adding fuel to the market growth.
By diagnosis, The Sad Market Is Segmented Into Physical Exam, Laboratory Tests, Psychological Evaluation, and Others.
The psychological evaluation segment is projected to grow at a significant rate during the forecast period. The segment consists of a multitude of tests, including personality tests, vocational tests, neuropsychological tests, aptitude tests, and direct observation tests. It is majorly driven by the rising number of companies and service providers offering psychological evaluation and the presence of a large number of trained clinical psychologists, organization behaviorists, neuropsychiatrists, and statisticians. For instance, PSYCHOMATRIX is a foremost organization involved in distribution, publication & training, and sales of psychological tests. The above-mentioned tests are extensively used by psychiatrists’ hospitals, school psychologists, psychologists educational institutes, clinical psychologists, neuropsychologists, health psychologists, and forensic psychologists, among others.
By the end-user, The Market Is Segmented Into Hospitals, Clinics, Household, Medical Research Centers, and Others.
The household segment is majorly driven by the growing awareness among populations regarding self-care, availability of online training sessions for improving the mental state, increasing adoption of smartphones and internet usage, and rising use of mental health applications. Currently, the online classes and mental therapy sessions are gaining huge popularity among the population as they offer umpteen services at relatively lower prices. In line with this, a number of key players are heavily investing in developing efficient digital health apps at competitive prices.
Regionally, the SAD Market is Segmented into the Americas, Europe, Asia Pacific, and The Middle East and Africa (MEA)
Americas are accounting for the highest share in the SAD market as the region is backed with the presence of various organizations that are dedicatedly working to increase awareness regarding SAD, such as the National Institute of Mental Health (NIMH), Mental Health America (MHA), and American Psychiatric Association. Also, the rising prevalence of SAD and mounting awareness regarding mental disorders are driving the market growth. For instance, around 5% of the Americans suffer from SAD every year, where 4 out of every 5 people are women. As per the study published by Cleveland Clinic, about half a million people in the U.S. suffer from winter SAD. Increasing prevalence of sedentary lifestyle, high consumption of junk food, excessive alcoholism, and smoking and drug abuse are some of the factors responsible for causing SAD, which is subsequently increasing the adoption of treatments and diagnosis.
Europe is second in the SAD market and will continue the same during the forecast period. For instance, around 2%–8% of the population is suffering from SAD. Additionally, the presence of a large number of hospitals and clinics offering wide treatment & diagnosis options for SAD patients is adding fuel to the market growth. In the U.K and Ireland, the prevalence of SAD is increasing at an alarming rate. However, increasing government funding for the development of advanced healthcare infrastructure is likely to boost the market growth in the years to come.
Asia Pacific is the fastest growing SAD market. This can be attributed to the growing geriatric population, changing lifestyle, increasing expenditure power, high adoption of mental counseling therapies, development of the healthcare sector, and availability of SAD treatments at lower prices. In India, a huge population is suffering from personal fatigue, depression, feeling of hopelessness, and social withdrawal, which is subsequently surging the prevalence SAD. As per the Indian Medical Association (IMA), SAD occurs four times more often in women than in men aged 18–30. The growing awareness about SAD is boosting the demand for mental health counseling, medication, yoga, and music therapy, among others.
MEA is emerging in the SAD market as the penetration of seasonal affective disorders treatment options is limited in the region. In Africa, low healthcare spending is impeding the penetration of SAD drugs. Also, lack of well-developed healthcare infrastructure, low presence of hospitals, clinics, and psychiatric research centers are hampering the market growth. To attend to the situation, the government in the region is arduously working to introduce various treatments, such as psychotherapy in the years to come. In the Middle East, the market is likely to experience positive growth on account of increasing healthcare expenditure, growing awareness regarding SAD, and increasing government initiatives for raising awareness regarding mental health and its effect on life.
The global SAD market has the presence of established players that are acquiring emerging players for expanding their portfolio and increasing their market share. The market is consolidated with the presence of AbbVie, Inc., Allerfan, Bayer AG, F-Hoffmann-La Roche Ltd., Henry Schien, Inc. Pfizer Inc., and Novartis AG.
Recently, Circadian Optics launched Lumine Light Therapy Lamp, AN ULTRA BRIGHT 10,000 lux full spectrum LED light. The lamp is featured with effective light therapy for treating SAD, fight fatigue, boost mood, improve focus, and regulate sleep.